Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp started coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a research note published on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $23.00 target price on the stock.

Other research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Mizuho started coverage on shares of Immix Biopharma in a report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Finally, Wall Street Zen upgraded shares of Immix Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Immix Biopharma Stock Performance

IMMX opened at $10.13 on Monday. The company has a market cap of $536.48 million, a price-to-earnings ratio of -13.16 and a beta of 0.25. Immix Biopharma has a one year low of $1.34 and a one year high of $10.50. The business’s fifty day moving average is $6.48 and its two-hundred day moving average is $4.55.

Institutional Trading of Immix Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP acquired a new stake in shares of Immix Biopharma during the fourth quarter valued at $30,000. Velan Capital Investment Management LP acquired a new position in Immix Biopharma in the 2nd quarter valued at about $52,000. Mathes Company Inc. acquired a new position in Immix Biopharma in the 4th quarter valued at about $56,000. Balyasny Asset Management L.P. purchased a new position in Immix Biopharma in the 4th quarter valued at about $67,000. Finally, Kera Capital Partners Inc. acquired a new stake in shares of Immix Biopharma during the 4th quarter worth about $68,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.